Physician profile
Jasdeep Sidana
NPI 1558482075
$12,816.47
in general payments reported to CMS, 2019-2025
34 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,253 · 2020: $1,308 · 2021: $802 · 2022: $165 · 2023: $483 · 2024: $276 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.39 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,479.83 | 2019-2025 | Jascayd, Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $1,878.46 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Genentech USA, INC. | $771.02 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $704.60 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Sunovion Pharmaceuticals INC. | $625.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $396.04 | 2019-2025 | |
| Inspire Medical Systems, INC. | $234.26 | 2024-2025 | Inspire |
| Mylan Specialty L.P. | $199.47 | 2019-2024 | Yupelri |
| Becton, Dickinson and Company | $157.70 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $140.90 | 2019-2025 | Dupixent |
| Pfizer INC. | $138.90 | 2019-2021 | |
| Viatris Specialty LLC | $135.89 | 2025 | Yupelri |
| Grifols USA, LLC | $119.12 | 2019 | |
| 3b Medical, INC. | $91.14 | 2025 | Luna |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $78.38 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Horizon Therapeutics Plc | $77.04 | 2019-2020 | |
| Verona Pharma, INC. | $74.67 | 2025 | Ohtuvayre |
| Amgen INC. | $69.61 | 2024-2025 | Tezspire |
| Electromed, INC. | $54.23 | 2021-2025 | Smartvest |
| Insmed, INC. | $50.05 | 2019-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $49.44 | 2020 | |
| Novo Nordisk INC | $33.55 | 2019-2023 | |
| Mission Pharmacal Company | $22.03 | 2019 | |
| Shire North American Group INC | $21.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.73 | 2020 | |
| Boston Scientific Corporation | $17.07 | 2024 | |
| Genzyme Corporation | $16.73 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.21 | 2019 | |
| Lilly USA, LLC | $14.49 | 2019 | |
| Merck Sharp & Dohme LLC | $13.83 | 2019 | |
| Echosens North America, INC. | $13.59 | 2024 | Fibroscan |
| Optinose US, INC. | $13.50 | 2019 | |
| Circassia INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasdeep Sidana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.